FY2026 EPS Forecast for CytomX Therapeutics Cut by Analyst

Key Points

• HC Wainwright has cut its FY2026 earnings per share estimate for CytomX Therapeutics from ($0.01) to ($0.02), maintaining a "Buy" rating with a target price of $5.00.
• CytomX Therapeutics recently reported earnings of $0.27 per share in its latest quarter, exceeding analyst estimates, and achieving a significant net margin of 34.04%.
• Despite the earnings forecast reduction, five analysts currently rate CytomX Therapeutics' stock as a "buy," with an average target price of $5.75.

CytomX Therapeutics, Inc. (NASDAQ:CTMX - Free Report) - Investment analysts at HC Wainwright reduced their FY2026 earnings per share estimates for shares of CytomX Therapeutics in a research note issued on Monday, August 11th. HC Wainwright analyst M. Kapoor now anticipates that the biotechnology company will post earnings per share of ($0.02) for the year, down from their previous estimate of ($0.01). HC Wainwright has a "Buy" rating and a $5.00 price objective on the stock. The consensus estimate for CytomX Therapeutics' current full-year earnings is ($0.05) per share. HC Wainwright also issued estimates for CytomX Therapeutics' Q4 2026 earnings at ($0.01) EPS.

CytomX Therapeutics (NASDAQ:CTMX - Get Free Report) last released its quarterly earnings data on Monday, May 12th. The biotechnology company reported $0.27 earnings per share for the quarter, topping the consensus estimate of $0.18 by $0.09. CytomX Therapeutics had a return on equity of 158.70% and a net margin of 34.04%. The business had revenue of $50.92 million during the quarter, compared to analysts' expectations of $35.42 million. During the same quarter last year, the business posted $0.17 EPS.

Other research analysts have also recently issued research reports about the company. Wall Street Zen upgraded CytomX Therapeutics from a "hold" rating to a "buy" rating in a research note on Tuesday, May 13th. Piper Sandler raised their target price on CytomX Therapeutics from $2.50 to $5.00 and gave the company an "overweight" rating in a research note on Thursday, May 15th. Wedbush restated an "outperform" rating and issued a $6.00 target price (up previously from $5.00) on shares of CytomX Therapeutics in a research note on Monday, May 12th. Finally, Oppenheimer started coverage on CytomX Therapeutics in a research note on Thursday, July 31st. They issued an "outperform" rating and a $7.00 target price for the company. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of "Buy" and an average target price of $5.75.

CytomX Therapeutics Stock Performance

NASDAQ CTMX opened at $1.90 on Wednesday. CytomX Therapeutics has a fifty-two week low of $0.40 and a fifty-two week high of $3.10. The stock has a 50 day simple moving average of $2.38 and a two-hundred day simple moving average of $1.47. The stock has a market cap of $152.78 million, a P/E ratio of 3.49 and a beta of 2.13.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. Assenagon Asset Management S.A. raised its stake in CytomX Therapeutics by 1.2% during the second quarter. Assenagon Asset Management S.A. now owns 720,020 shares of the biotechnology company's stock valued at $1,634,000 after buying an additional 8,566 shares during the last quarter. Vanguard Personalized Indexing Management LLC raised its stake in CytomX Therapeutics by 63.6% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 28,966 shares of the biotechnology company's stock valued at $66,000 after buying an additional 11,258 shares during the last quarter. Northern Trust Corp raised its stake in CytomX Therapeutics by 16.0% during the fourth quarter. Northern Trust Corp now owns 150,632 shares of the biotechnology company's stock valued at $155,000 after buying an additional 20,746 shares during the last quarter. Jacobs Levy Equity Management Inc. raised its stake in CytomX Therapeutics by 1.5% during the fourth quarter. Jacobs Levy Equity Management Inc. now owns 1,547,215 shares of the biotechnology company's stock valued at $1,594,000 after buying an additional 23,139 shares during the last quarter. Finally, Miller Financial Services LLC raised its stake in CytomX Therapeutics by 104.0% during the first quarter. Miller Financial Services LLC now owns 51,000 shares of the biotechnology company's stock valued at $32,000 after buying an additional 26,000 shares during the last quarter. Hedge funds and other institutional investors own 67.77% of the company's stock.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.